A practical reference on Fifteen residues: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
=== Comorbid disorders === People with comorbid mental health conditions such as depression, anxiety, attention deficit hyperactivity disorder or post-traumatic stress disorder are more likely to develop substance use disorders.
== Personal life == Zverev lives in Monte Carlo, Monaco. He grew up in Hamburg and also has spent his winters living in Florida at the Saddlebrook Academy. He can speak German, Russian, and English. Zverev has a daughter, Mayla, who was born in 2021 to Brenda Patea, an ex-girlfriend. Both parents reached an out-of-court financial settlement after a lawsuit over alleged physical assault was filed against Zverev by the ex-partner in 2023. Since 2021, Zverev has been dating German actress Sophia Thomalla. In 2017, Zverev said that his tennis idol is Roger Federer. He is a fan of the Miami Heat and Bayern Munich and wore the jersey of Bayern player Michael Olise during the 2026 BMW Open. In his spare time, he enjoys playing basketball and golf. His best friend on the tennis tour is Brazilian doubles specialist Marcelo Melo. He is also close friends with Dominic Thiem and Andrey Rublev, and has known the latter since childhood. Zverev filed a lawsuit against the ACE Group International and its CEO, Patricio Apey, accusing them of "unlawful restraint of trade". He argued that the contract between them was oppressive, but eventually agreed to settle the dispute out of court before the trial began.
During the remainder of the war, Cossack units were dismounted to fight in trenches, held in reserve to exploit a rare breakthrough, or assigned various duties in the rear. Those duties included rounding up deserters, providing escorts to war prisoners, and razing villages and farms in accordance with Russia's scorched earth policy.
Sources: en.wikipedia.org
The Pd2(dba)3/MePhos catalytic system has been applied to late stage Suzuki cross couplings. This reaction has been conducted on a kilogram (2.2 lbs)scale, and no specific palladium-removal treatment was required as the excess imidazole present in the final amide coupling step coordinated to the Pd and generated a removable byproduct.
The price of real estate in Moscow continues to increase. The expected price averages $4,000 per square meter (11 sq ft) near the perimeter of the city or $6,500–8,000 per square meter in a prestigious district. The price sometimes exceeds $40,000 per square meter for a flat. Renting costs about $1,200 per month for a one-bedroom apartment and about $1,000 per month for a studio in the city center. A typical one-bedroom apartment in Moscow is about 30 square meters (320 square feet) in area; a typical two-bedroom apartment is 45 square meters (480 square feet); and a typical three-bedroom apartment is 70 square meters (750 square feet). Many residents cannot move out of their apartments, especially if a family lives in a two-room apartment originally granted by the state during the Soviet era. Some city residents have attempted to cope with the cost of living by renting out their apartments while staying in dachas (country houses) outside the city. In 2006, Mercer Human Resources Consulting named Moscow the world's most expensive city for expatriate employees, ahead of recurring winner Tokyo, because of the stable Russian ruble as well as increasing housing prices. Moscow also ranked first in the 2007 edition and 2008 edition of the survey. However, in 2009, Tokyo overtook Moscow, which came in third after Osaka. In 2014, according to Forbes magazine, Moscow was ranked the world's ninth most expensive city. This magazine ranked Moscow the second most expensive city the previous year.
== Structure == Mammalian GPX1, GPX2, GPX3, and GPX4 (this protein) have been shown to be selenium-containing enzymes, whereas GPX6 is a selenoprotein in humans with cysteine-containing homologues in rodents. In selenoproteins, the amino acid selenocysteine is inserted in the nascent polypeptide chain during the process of translational recoding of the UGA stop codon. GPX4 shares the amino acid motif of selenocysteine, glutamine, and tryptophan (catalytic triad) with other glutathione peroxidases.
=== Aliases === As with many other genes, there are some common aliases found with this gene. Those aliases are Lymphocyte-Activation Gene-1 (LAG1) Interacting Protein, Transparent Testa Glabra 1 (TTG1), and Odorant Response Abnormal 4 (ODR4). The most common alias for C1orf27 is ODR4, and this is what most readily appears when searching the gene.
Sources: en.wikipedia.org
At the highest assessed dose in castrated male rats, levator ani weight was increased to around 140% of that of gonadally intact controls, whereas prostate weight was only increased to around 45% of that of intact controls. The tissue selectivity of LGD-4033 was independent of local tissue drug concentration, suggesting that its selectivity was intrinsic. The muscle-stimulating effects of LGD-4033 have also been confirmed in humans in preliminary clinical trials. The data also allow comparison between different SARMs and other AR agonists. In a phase 1 clinical trial in 76 healthy young men, 1 mg/day LGD-4033 increased lean body mass by 1.2 kg after 3 weeks of treatment. For comparison, enobosarm, another SARM, increased lean body mass by 1.3 kg at a dose of 3 mg/day after 12 weeks in healthy elderly men and postmenopausal women. It was concluded that the employed dose of LGD-4033 produced similar increases in lean body mass compared to enobosarm despite a substantially shorter treatment period. In a phase 2 clinical trial in 108 women and men with hip fracture, LGD-4033 increased lean body mass by 4.8% at 0.5 mg/day, 7.2% at 1 mg/day, and 9.1% at 2 mg/day after 12 weeks of treatment. For comparison, lean body mass with enobosarm 3 mg/day after the same time period of 12 weeks increased by about 0.30% at 0.1 mg/day, 0.40% at 0.3 mg/day, 1.2% at 1 mg/day, and 3.1% at 3 mg/day, with only the latter change achieving statistical significance.
Lücking and colleagues (2021) emphasize distinguishing real species from minor variants with differing allele frequencies or subtle sequence divergence. These issues reflect the balance between scientific progress and maintaining a practical, stable nomenclature for ecological and conservation work. The LPR framework is one attempt to impose a higher bar: requiring evidence of reproductive isolation or ecological differentiation, not just genetic distinctness, to call something a new species. Additionally, nomenclatural stability is an ongoing issue. When molecular studies reorder relationships, it often necessitates changes in genus or family assignments. The 2016 global lichen classification (and its 2017 update) made hundreds of such changes to align names with phylogeny. They noted that fully half of all lichen genera had to be moved to a different family or order compared to the previous decade's understanding. These scientifically justified changes can be disruptive for end-users like ecologists or land managers who suddenly have to learn new names for familiar organisms. The challenge for systematists is to communicate these changes clearly and perhaps even temper the pace of renaming by holding off until results are strongly corroborated. Some stability measures (like proposing nomenclatural conservation of widely used names even if they are technically nested in another group) can mitigate the impact on the broader community.
This name was officially adopted by the International Union of Pure and Applied Chemistry (IUPAC) in 1949, becoming the second element after gallium to be named after France. It was assigned the symbol Fa, but it was revised to the current Fr shortly thereafter. Francium was the last element discovered in nature, rather than synthesized, following hafnium and rhenium. Further research into francium's structure was carried out by, among others, Sylvain Lieberman and his team at CERN in the 1970s and 1980s.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.